CytoDyn Inc. (CYDY)
OQB · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Quarterly Financials
| Metric | 2025-05-31 | 2025-11-30 | 2026-02-28 | 2026-05-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (5.1M) | (5.1M) | (6.3M) | (6.8M) |
| Net Income | (6.0M) | (22.6M) | (4.7M) | (9.9M) |
| Diluted EPS | N/A | $-0.02 | $0.00 | N/A |
Annual Financials
| Metric | 2023-05-31 | 2024-05-31 | 2025-05-31 | 2026-05-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | |
| Gross Profit | (20.6M) | 0.00 | ||
| Operating Income | (40.6M) | (18.1M) | 9.7M | |
| Net Income | (79.8M) | (49.8M) | 3.7M | |
| Diluted EPS | $-0.10 | $-0.05 | $0.00 | $-0.03 |